We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

16 hedge funds and large institutions have $5.79M invested in Outlook Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 15 → 16 (+1)

0.01% less ownership

Funds ownership: 0.16% → 0.15% (-0.01%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

64% less capital invested

Capital invested by funds: $16M → $5.79M (-$10.2M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$225K
2
PAM
Panagora Asset Management
Massachusetts
+$114K
3
BlackRock
BlackRock
New York
+$57.1K
4
Wells Fargo
Wells Fargo
California
+$17.5K
5
ASN
Advisory Services Network
Georgia
+$3.67K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$607K
2
LCM
Landscape Capital Management
New Jersey
-$35K
3
Millennium Management
Millennium Management
New York
-$28.8K
4
JAM
JW Asset Management
Florida
-$14K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$6.78K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$2.37M +$225K +796 +6%
CAM
2
Cormorant Asset Management
Massachusetts
$1.01M – – –
PA
3
Perceptive Advisors
New York
$837K -$607K -2,150 -29%
ACA
4
Avoro Capital Advisors
New York
$684K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$285K – – –
MWNA
6
Marshall Wace North America
New York
$262K – – –
BCM
7
Bridgeway Capital Management
Texas
$139K – – –
PAM
8
Panagora Asset Management
Massachusetts
$65K +$114K +405 New
BlackRock
9
BlackRock
New York
$32K +$57.1K +202 New
Millennium Management
10
Millennium Management
New York
$31K -$28.8K -102 -34%
ACP
11
Acuta Capital Partners
California
$29K – – –
Morgan Stanley
12
Morgan Stanley
New York
$21K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$11K -$6.78K -24 -26%
Wells Fargo
14
Wells Fargo
California
$10K +$17.5K +62 +6,200%
UBS Group
15
UBS Group
Switzerland
$2K – – –
ASN
16
Advisory Services Network
Georgia
$2K +$3.67K +13 New
LCM
17
Landscape Capital Management
New Jersey
– -$35K -82 Closed
JAM
18
JW Asset Management
Florida
– -$14K -32 Closed

OTLK Hedge Fund Activity: Q2 2017 in Review

16 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2017, worth a combined $5.79M — down 64% from $16M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new OTLK positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Sabby Management, adding an estimated $225K. The largest seller was Perceptive Advisors, cutting an estimated $607K.

  • 16 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2017, up from 15 in Q1 2017.
  • Funds reported $5.79M of Outlook Therapeutics stock for Q2 2017, down 64% quarter-over-quarter.
  • 3 funds opened new Outlook Therapeutics positions in Q2 2017 and 2 closed out, a net change of +1 holder.
  • The largest Outlook Therapeutics buyer in Q2 2017 was Sabby Management, an estimated $225K added.
  • The largest Outlook Therapeutics seller in Q2 2017 was Perceptive Advisors, an estimated $607K sold.

Based on aggregated 13F filings for Q2 2017.